HSBC analyst Rajesh Kumar lowered the firm’s price target on Roche (RHHBY) to CHF 365 from CHF 385 and keeps a Buy rating on the shares. The firm says the uncertain macro backdrop, rising geopolitical risk, and lower exposure to AI disruption risks could attract investors to healthcare and drive outperformance in the coming quarter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche downgraded to Neutral from Outperform at BNP Paribas
- District court rules federal limits to vaccines not based on science, NYT says
- Piper Sandler biotech analysts hold analyst/industry conference call
- Roche receives CE Mark for Elecsys Apolipoprotein E4 test
- Roche price target lowered to CHF 325 from CHF 350 at JPMorgan